Farallon Capital Management LLC Lowers Stake in IQVIA Holdings Inc. (NYSE:IQV)

Farallon Capital Management LLC lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 1.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,123,151 shares of the medical research company's stock after selling 47,932 shares during the quarter. IQVIA comprises about 3.1% of Farallon Capital Management LLC's investment portfolio, making the stock its 7th biggest holding. Farallon Capital Management LLC owned 1.72% of IQVIA worth $613,730,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Principal Financial Group Inc. boosted its stake in IQVIA by 0.8% in the 3rd quarter. Principal Financial Group Inc. now owns 209,021 shares of the medical research company's stock worth $49,532,000 after purchasing an additional 1,750 shares during the period. JPMorgan Chase & Co. boosted its stake in IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock worth $437,378,000 after purchasing an additional 583,396 shares during the period. Wealth Enhancement Advisory Services LLC boosted its stake in IQVIA by 1.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company's stock worth $1,068,000 after purchasing an additional 56 shares during the period. Czech National Bank boosted its stake in IQVIA by 6.0% in the 4th quarter. Czech National Bank now owns 37,386 shares of the medical research company's stock worth $7,347,000 after purchasing an additional 2,107 shares during the period. Finally, Claro Advisors LLC acquired a new stake in shares of IQVIA during the 4th quarter valued at $281,000. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Stock Performance

Shares of NYSE:IQV traded down $4.39 on Friday, hitting $148.90. 1,677,229 shares of the company were exchanged, compared to its average volume of 1,469,448. The company's 50 day moving average price is $163.91 and its two-hundred day moving average price is $188.09. IQVIA Holdings Inc. has a one year low of $135.97 and a one year high of $252.88. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The firm has a market capitalization of $25.76 billion, a price-to-earnings ratio of 19.85, a PEG ratio of 1.99 and a beta of 1.34.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The company had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. During the same quarter in the previous year, the firm posted $2.54 EPS. The business's revenue was up 2.5% compared to the same quarter last year. Research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on IQV. Barclays decreased their target price on shares of IQVIA from $170.00 to $165.00 and set an "equal weight" rating for the company in a research note on Wednesday. Truist Financial cut their price target on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a report on Thursday, April 10th. Morgan Stanley raised their price target on shares of IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a report on Tuesday, February 11th. Citigroup cut their price target on shares of IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Finally, UBS Group cut their price target on shares of IQVIA from $255.00 to $185.00 and set a "buy" rating on the stock in a report on Wednesday. Eight equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $231.71.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.